# Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for

Source: https://onco.cc/trials/nct06872606/  
OnCo record `nct06872606` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pucotenlimab, bevacizumab (glioblastoma use) and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Sir Run Run Shaw Hospital, not yet recruiting.

## Summary

Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer is a phase 2, interventional study registered as NCT06872606 by Sir Run Run Shaw Hospital, with a registry enrolment figure of 33 participants, started 2025-04-01 and due to reach its primary completion in 2026-04-01. Interventions recorded: Pucotenlimab; Bevacizumab; Oxaliplatin; Trifluridine/Tipiracil Hydrochloride; Short-course radiotherapy; intracavitary brachytherapy. Conditions listed: Rectal Adenocarcinoma. Primary outcome: Organ preservation rate. Colorectal eligibility wording from the registry: "Diagnosed by digital rectal examination, colonoscopy, and high-resolution MRI of the pelvis, the tumor is less than or equal to 5 cm from the anus". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: SCRIPBOT
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06872606
- Phase: 2
- Setting: The Efficacy and Safety of Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Adenocarcinoma: an Prospective, Single Arm Clinical Trial （SCRIPBOT Trial）
- Sponsor: Sir Run Run Shaw Hospital
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT06872606: https://clinicaltrials.gov/study/NCT06872606

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Pucotenlimab](https://onco.cc/drugs/pucotenlimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06872606.json